Amarin Announces Proposed Public Offering of American Depositary Shares
August 10 2016 - 4:10PM
Amarin Corporation plc (NASDAQ:AMRN) today announced that it has
commenced an underwritten public offering of its American
Depositary pursuant to a shelf registration. All of the
shares in the proposed offering are to be sold by Amarin. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
Jefferies LLC and Citigroup Global Markets Inc. are acting as
joint book-running managers in the offering. Cantor Fitzgerald
& Co. is acting as lead manager and H.C. Wainwright & Co.
and SunTrust Robinson Humphrey are acting as co-managers in this
offering. Amarin intends to grant the underwriters a 30-day option
to purchase additional shares of its common stock in an amount up
to 15% of the shares sold in the offering, on the same terms and
conditions.
The securities described above are being offered by Amarin
pursuant to a shelf registration statement on Form S-3 (No.
333-197936) previously filed with the Securities and Exchange
Commission (the "SEC") on August 7, 2014 and declared effective by
the SEC on August 22, 2014. A preliminary prospectus supplement
related to the offering will be filed with the SEC and will be
available on the SEC's website at http://www.sec.gov. Copies of the
preliminary prospectus supplement relating to these securities may
be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com or from Citigroup Global
Markets Inc., c/o Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
by any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health. Vascepa® (icosapent ethyl) capsules,
Amarin's first FDA approved product, are a highly-pure, omega-3
fatty acid product available by prescription.
Disclosure Notice
This press release contains forward-looking statements, within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements related to Amarin's public offering of
American Depositary Shares, are forward-looking statements that
involve risks and uncertainties. Words such as "intends," "plans,"
"expects," "may," "will" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are not promises or guarantees. These forward-looking
statements are based upon Amarin's current expectations. Actual
events and results and the timing of events and results could
differ materially from those anticipated in such forward-looking
statements. Among the factors that could cause actual results
to differ materially from those described or projected herein are
the following: risks related to the underwriters' consummation of
their obligation to purchase the securities, whether Amarin will be
able to satisfy its obligations to close the offering and the risk
that Amarin will not use the proceeds from the offering in the
manner contemplated, as well as the risks, uncertainties and other
matters detailed in Amarin's filings with the U.S. Securities and
Exchange Commission, including its most recent Annual Report on
Form 10-K, its most recent Quarterly Report on Form 10-Q and the
preliminary prospectus supplement relating to the offering.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date they were made. Amarin undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise, except as required by law.
Amarin contact information:
Investor Relations:
Kathryn McNeil
Investor Relations and Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries:
Kristie Kuhl
Finn Partners
In U.S.: +1 (212) 583-2791
Kristie.kuhl@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024